Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

著者: Meletios Α. Dimopoulos, Hang Quach, María‐Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Hui Yang, Zandra Klippel, Anita Zahlten‐Kumeli, Saad Z. Usmani - The Lancet 2020 被引用: 422